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The adrenal cortex regulates renal function in a
number of important ways; indeed, normal renal func-
tion cannot be understood without recognition of such
regulation. Well-recognized examples of such regula-
tion are the control of body fluid tonicity through reg-
ulation of urinary solute concentration—a function
controlled "primarily" by vasopressin, but secondarily
and importantly by the adrenal cortex—and control of
body sodium—a function controlled primarily by renal
tubular sodium reabsorption but regulated by sodium-
retaining steroids.
The kidney can regulate adrenal function by chang-
i ng reabsorption of sodium and secretion of potassium,
and also by release of renin. The primary target of such
regulation is the secretion of aldosterone, which may
be influenced by body fluid volume, potassium ion and
angiotenSin II.
Because of these interrelationships, the pathophysio-
logy of certain disease states may be described as
aberrations in feedback loops between adrenal cortex
and kidney. In this paper we will consider this "sys-
tem" in some detail, and attempt to explain four dis-
orders as examples of errors in control.
In the form of "primary" aldosteronism resulting
from hyperplasia of all adrenal cortical tissue, over-
production of aldosterone persists in the absence of all
known stimulatory factors. In renovascular hyper-
tension, angiotensin and aldosterone production may
persist despite systemic hypertension. In the non-salt-
losing form of the adrenogenital syndrome of con-
genital adrenal hyperplasia without treatment, failure
of feedback inhibition by cortisol may result in over-
production of adrenocorticotropic hormone (ACTH)
which, in turn, may lead to overproduction of pro-
gesterone. Progesterone may cause sodium loss and
overproduction of renin and aldosterone while block-
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ing their effects. In the syndrome of juxtaglomerular
hyperplasia with normal blood pressure, overproduc-
tion of renin may result from unresponsiveness of
blood vessels leading to a lack of feedback inhibition
by pressure rise. Under certain circumstances sodium
loss can potentiate both the overproduction and the
unresponsiveness. Excessive renin leads to aldosteron-
isni and potassium loss.
Adrenal cortical control of renal function
The control of renal function by the adrenal cortex
can best be considered separately for steroids with
predominately carbohydrate-regulating activity, e.g.,
cortisol, and for those with sodium-retaining activity,
e.g., aldosterone.' In addition, progesterone may act as
an aldosterone antagonist [51.
Cortisol increases the glomerular filtration rate
(GFR) and, thus, the filtered load of sodium and water
[6, 7]. In its absence, the GFR falls, and excretion of
salt and water loads is limited. A second action of
cortisol, in decreasing distal tubular reabsorption of
water, must be invoked to explain the limitation of free
water clearance in its absence [8, 9]. This limitation
can be overcome with doses of carbohydrate-active
steroids which do not increase the GFR [8].
Aldosterone has no effect on GFR except as GFR
may be influenced by sodium retention and expansion
1 The designations "glucocorticoid" and "mineralocorticoid",
used as nouns for such steroids, introduce semantic and, more
importantly, conceptual difficulties. Thus, rapid excretion of
potassium is a function of carbohydrate-active steroids, not of
sodium-retaining ones [1], whereas sodium-retaining steroids
may cause potassium retention [2]. A fluorine atom in the 9-alpha
position increases both carbohydrate activity (10-fold) and
sodium-retaining activity (125-fold) [3]. The naturally occurring
steroid corticosterone has both properties; indeed, cortisol pro-
duces sodium retention. ACTH stimulates not only aldosterone
secretion by the zona glomerulosa but also desoxycorticosterone
secretion by the zona fasciculata [4].
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of extracellular fluid volume. It has no effect on distal
tubular reabsorption of solute-free water, and cannot
improve the water diuresis in Addison's disease.
Aldosterone may increase sodium reabsorption a) in
the proximal tubule [10—12], b) in the ascending limb
of the loop of Henle [13], c) in the distal convoluted
tubule [14] and d) in the collecting ducts [15]. In the
last two sites, the increase in negative luminal potential
produced by the reabsorption of sodium facilitates
secretion of potassium [14] so that potassium appears
to "exchange" for reabsorbed sodium. In the same
two sites, secretion of hydrogen ion, facilitated by the
potential difference, may also be promoted by aldo-
sterone [16, 17].
Aldosterone also affects another renal function, to
wit, release of renin. Whereas this has great clinical im-
portance, in that renin release is suppressed in primary
aldosteronism, the mechanism(s) by which this is
accomplished is unknown. The suppression clearly
does not result from hypertension per se, since the
same degree of "essential" hypertension need not have
the same effect; it occurs despite persistently low
plasma potassium concentration, which should raise
renin production. It may reflect renal vasoconstriction
more "distal" than that found in "essential" hyper-
tension, allowing the pressure rise to be sensed by the
juxtaglomerular apparatus.
Progesterone can antagonize the effect of sodium-
retaining steroids [5] on the renal tubules [18] reducing
the retention of sodium produced by a given dose of
aldosterone or desoxycorticosterone at a given filtered
load. This effect (vide infra) may explain the secondary
aldosteronism of the non-salt-losing form of the adren-
ogenital syndrome.
Renal control of adrenal cortical function
The kidneys can control aldosterone secretion
directly, by changes in renin secretion, leading to
changes in release of angiotensin I, which is converted
to angiotensin II, and indirectly, by retention of sodium
or by retention or loss of potassium.
Release of renin has been accomplished experimen-
tally with diuretic administration and sodium de-
privation [19—23], catecholamine [24, 25] or cyclic
AMP [25, 26] administration, potassium deprivation
[27—29], renal nerve stimulation [30—33], hemorrhage
[34—36] and renal artery constriction [34, 35, 37, 38].
Accordingly, the precise mechanism of release in a
given subject or syndrome may be difficult to assess.
With many but not all of these stimuli, beta-blockade
of the autonomic nervous system blocks renin release.
It is clear that volume contraction, as with sodium loss,
and pressure changes, as with renovascular constric-
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Fig. 1. "Feedback" loops involved in blood pressure control.
The schema shows a decrease in total body sodium leading to
a decrease of extracellular (ECF) volume (solid arrow), and
lowering blood pressure (open arrow). 17-Hydroxyprogesterone
(and also progesterone) can decrease body sodium through renal
loss. ECF volume decrease produces an increase of renin which
may increase blood pressure. An increase of renin produces an
increase of aldosterone which may also increase blood pressure.
An increase in aldosterone secretion decreases body potassium
through renal loss, and a decrease in potassium may inhibit
aldosterone production and stimulate renin production. Finally,
a rise of blood pressure may directly inhibit renin release. (Note
that FCF volume and renal arterial blood pressure control
plasma renin independently.) Production of aldosterone is also
under control of AcTH, and progesterone and 1 7-hydroxy-
progesterone are by-products.
tion, can each serve as an independent stimulus to renin
release. Experimentally, procedures which increase
transport of sodium at the region of the macula densa
decrease renin production.
Renal retention of sodium can lower aldosterone
production by suppression of renin production and
also probably by mechanism(s) not involving renin
[39]. Renal loss of potassium can similarly depress
aldosterone production, probably as a direct cellular
effect [40, 41].
Some of these relationships involved in adrenal-
renal interaction are illustrated in Fig. 1.
The syndrome of primary aldosteronism resulting from
primary adrenocortical hyperplasia considered as an
error in feedback control
In the syndrome of primary aldosteronism resulting
from adrenocortical adenoma, or Conn's syndrome,
the sequence of events (adrenal adenoma -±overpro-
duction of aldosterone —÷ hypertension — renin sup-
pression) appears well-established even though the
mechanism of renin suppression, like the mechanism
for hypertension, is not clear.
The clinical criteria for diagnosis depend upon a) de-
monstration of overproduction of aldosterone and
b) demonstration that such overproduction is "auto-
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nomous", e.g., in the face of expansion of ECF and of
intravascular volume. This can be attempted 1) with
sodium loads or 2) with albumin given i.v.
When overproduction is "autonomous", sodium
loads lower the serum and body potassium concentra-
tions—a point of diagnostic value (vide infra). Potas-
sium loss, per Se, however, can lower aldosterone
secretion. Thus, overproduction may appear to be
nonautonomous, vis-a-vis body fluid volume when
expansion with sodium loads lowers serum potassium
and lowers aldosterone secretion by this mechanism.
Expansion of intravascular volume can be accom-
plished with albumin infusion, and this does not pro-
duce potassium loss.
A third criterion for diagnosis is c) the suppression of
plasma renin activity. As suppression is normally in-
duced by sodium loads, the possibility of suppression
in primary aldosteronism is sought after volume con-
traction—generally with low sodium-diet and ad-
ministration of diuretics.
A fourth criterion for steroid "autonomy" in
primary aldosteronism lies in d) the ability of sodium
loads to lower body and pJasma potassium concentra-
tion [42]. This effect depends both upon the autonomy
of aldosterone secretion in relation to the sodium load
and upon the effect of aldosterone in potentiating
distal tubular potassium secretion: with sodium loads,
increases in absolute distal reabsorption of sodium, the
(lumen negative) electrical potential for such secretion
is presumably increased [14].
Fig. 2 illustrates these criteria in a patient with
Conn's syndrome of primary aldosteronism resulting
from adenoma. This patient presented with severe
hypertension and hypokalemia. Sodium deprivation
(July 7 to 20) 1) lowered blood pressure, 2) restored
serum potassium concentration to normal and 3) failed
to stimulate plasma renin activity, which on the last
day was 1.8 ng/ml/min with the patient supine and
essentially unchanged with the patient upright.
Sodium loading (July 20 through 27) 1) raised blood
pressure, 2) lowered serum potassium concentration to
2.0 mEq/liter and 3) lowered the aldosterone secretion
rate only slightly: it was 734 sg/24 hr on the 8th day of
the sodium load as compared to 1000 g/24 hr on the
12th day of sodium deprivation. The effective reversal
of hypertension and hypokalemia with aldosterone
antagonists and the reversal of all findings with removal
of the adrenocortical adenoma argue strongly for the
sequence of events we have described.
The appearance of a syndrome of primary hyperplasia
of the adrenal cortex leading to the full syndrome of
primary aldosteronism [42—44] has posed important
questions: a practical one of differential diagnosis, and
a theoretical one of explaining control of aldosterone
Fig. 2. Effect of low and high sodium intakes on blood pressure,
serum and urinary sodium (Na), serum and urinary potassium (K),
body wt, aidosterone secretion rate (ASR) and plasma renin
activity (PRA) in a 54-yr-old white female patient with primary
aldosteronism resulting from an adenoma.
secretion independently of ACTH, angiotensin and
potassium ion.
Fig. 3 illustrates the results in a patient with the
syndrome of primary aldosteronism resulting from
"primary" hyperplasia of all adrenal cortical tissue.
This patient presented with severe hypertension and a
normal plasma potassium concentration (4.6 mEq/
liter). With sodium intake of 109 mEq/day, serum
potassium concentration decreased to 4.0 mEq/Iiter,
aldosterone secretion rate was 1,151 tg/day (normal
for this sodium intake, less than 200 sg/day) and
plasma renin activity was 0. On a sodium intake of
249 mEq/day, serum potassium concentration de-
creased to 3.4 mEq/liter. With mercurial diuretic ad-
ministration (February 16), there was a 2.2 kilo weight
loss, but plasma renin activity (with the patient supine
or upright) remained at zero.
We have studied 13 patients shown to have this
syndrome. All of them have shown overproduction of
aldosterone and hypertension. Sodium loads could not
lower aldosterone secretion significantly, but did lower
serum potassium concentration in all; infusion of
albumin did not lower aldosterone secretion; plasma
renin was suppressed despite administration of a low-
sodium diet and diuretics.
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Fig. 3. Effect of normal, high and low sodium intakes on blood pres-
sure, serum and urinary sodium (Na), serum and urinary potas-
sium (K), body wt, aldosterone secretion rate (ASR) and plasma
renin activity (PRA) in a 57-yr-old male patient with primary
aldosteronism resulting from adrenal hyperplasia.
It is not possible to fit the syndrome of primary
aldosteronism with adrenal hyperplasia into the
schema of Fig. 1, since none of the stimuli to aldo-
sterone production in that schema will account for the
aldosteronism. Specifically, ACTH cannot be involved,
since all these patients secreted normal amounts of
cortisol and of 17-ketosteroids, and the syndrome could
not be suppressed by treatment designed to suppress
ACTH. Clearly, the adrenal overactivity cannot result
from elevated plasma renin or potassium concentra-
tions, since each of these is suppressed to subnormal
values. Accordingly, the existence of the syndrome
provides prima facie evidence for a stimulus, as yet un-
known, to aldosterone secretion.
Renal vascular hypertension as an error of
feedback control
Since the discovery by Tigerstadt and Bergman [37]
that constriction of a renal artery induces ipsilateral
release of renin, which in turn can raise blood pressure
by release of angiotensin, hypertension of renovascular
disease has been satisfactorily explained in many cases
according to this sequence of events.
A number of differences, however, prevent accept-
ance of this explanation for all renovascular hyper-
tension.
1. It was shown that whereas antibodies to angio-
tensin [45] and renin [46] could reverse the early
hypertension of experimental renal artery constriction,
such hypertension soon becomes refractory to such
antibodies.
2. It was shown that plasma renin becomes normal
in experimental renovascular hypertension when the
opposite kidney is removed [47]. Furthermore, sarco-
sine 1, ala 8-angiotensin, which appears to block endo-
genous angiotensin specifically in the rat [48], will
lower blood pressure in the two-kidney animal with
renal vascular constriction, but will not do so when the
opposite kidney has been removed [45].
In those species (dog and man) in which angiotensin
increases aldosterone secretion, it is likely that in reno-
vascular hypertension, if it results from sustained
overproduction of angiotensin, there should also be
sustained hypersecretion of aldosterone. This need not
be true either in the dog [49] or in patients with reno-
vascular hypertension [50].
Clinically it has been found that a number of patients
with renovascular constriction and hypertension may
have normal plasma renin activity and normal aldo-
sterone secretion, and yet respond to removal of the
constriction with a lowering of the blood pressure. It
may be that some factor(s) other than renin is released
or inactivated by the kidney with vascular constriction
or that the current methods of measuring plasma renin
activity do not measure the "effective" 24-hr angio-
tensin-producing capacity of the system.
We here describe a patient with renovascular con-
striction, hypertension, overproduction of aldosterone
and normal renin activity, whose hypertension, none-
theless, responded only to beta blockade and to surgi-
cal release of the constriction.
Fig. 4A shows the metabolic data on a 39-yr-old
woman with renovascular hypertension resulting from
bilateral fibromuscular hyperplasia. This patient pre-
sented with a six-year history of hypertension, hypo-
kalemia (K= 3.2 mEq/liter) and normal plasma renin
activity and high aldosterone secretion rates partly
suppressible by high-sodium diet. As shown in the
chart (Fig. 4B), hypertension persisted despite com-
bined treatment with alpha-methyldopa, 3 g/day;
hydralazine, 200 mg/day; hydrochlorothiazide, 50 mg/
day; and spironolactone (Aldactone), 400 mg/day.
The patient's blood pressure was completely controlled
with beta blockade when propranolol was superim-
posed (days June 28 through July 17); when pro-
pranolol was discontinued, the blood pressure returned
to daily average values of 168/127 mmHg.
Fibromuscular hyperplasia was demonstrated radio-
75 ASR
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graphically and corrected surgically, and the hyper-
tension was cured.
It is clear that in this patient the fibromuscular
hyperplasia increased renin production, and that such
overproduction was, at least in part, dependent upon
beta-adrenergic regulation [32]. The overproduction of
renin had a relatively greater effect on blood pressure
than on aldosterone production.
The sequence of events (renovascular constriction —-
Serum Na
mEq/day
5.01 Serum K
4.0J -
3.0 100
mEq/day
renin release — blood pressure rise and aldosterone
secretion —* hypokalemia) explains the symptom com-
plex. The effect of salt loading in decreasing renin
activity suggests that this control mechanism is not
without effect, despite the overriding stimulus of
vasoconstriction.
The secondary aldosteronism of adrenal hyperplasia,
non-salt-losing, as an error in feedback control
In the adrenogenital syndrome resulting from con-
genital adrenal hyperplasia, patients with the non-salt-
losing form regularly show hypersecretion of aldo-
sterone [51, 52]. In Fig. 5, this is shown for an average
and low-salt diet for nine patients with the syndrome
contrasted with results for normal subjects and results
of the same procedure for five subjects with the salt-
losing variety, in whom aldosterone production is very
low. Despite the hyperaldosteronism, it is noteworthy
that the patients with the non-salt-losing form of the
disorder have not been reported to show hypertension,
and do not suffer from hypokalemic alkalosis, a com-
plication expected in subjects with autonomous hyper-
secretion of aldosterone.
Both of these forms of the adrenogenital syndrome
of congenital adrenal hyperplasia have been shown to
result from a deficiency in the adrenal 21-hydroxylase,
required for conversion of 1 7-hydroxyprogesterone to
1 1-deoxycortisol. There results a limitation in produc-
tion of cortisol, with failure of plasma cortisol to
inhibit ACTH production normally, and a consequent
overproduction of ACTH, leading to overproduction
of progesterone and of 1 7-hydroxyprogesterone. The
progesterone and 1 7-hydroxyprogesterone can act as
Fig. 4. A, Effect of low and high sodium intakes on
blood pressure, serum and urinary sodium (Na),
serum and urinary potassium (K), aldosterone secre-
tion rate (ASR), and plasma renin activity in a 38-
yr-old white female patient with renovascular hyper-
tension. B, Effect of antihypertensive agents on blood
pressure and serum sodium (Na) and potassium (K)
in the same patient. HCT, hydrochiorothiazide,
Note that the blood pressure does not return to-
ward normal until propranolol is added. Later,
propranolol alone controlled the blood pressure.
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antagonists of sodium-retaining hormones [5, 53] and
induce renal sodium loss. Such renal sodium loss leads
to overproduction of renin and overproduction of
aldosterone [51, 52]. Because such overproduction of
aldosterone is compensatory, resulting from sodium
loss of renal tubular origin, it does not produce the
hypertension or the hypokalemic alkalosis that result
from autonomous overproduction.
The suppression of ACTH in this syndrome
promptly lowers not only the excessive excretion of
17-ketosteroids, by-products of the overproduction of
1 7-hydroxyprogesterone, but also aldosterone produc-
tion to the value normal for the sodium intake [51].
This syndrome thus appears as an error in feedback
control of aldosterone production, presenting with the
following sequence of events: cortisol deficiency —-
ACTH excess -± overproduction of progesterone and
17-hydroxyprogesterone —÷ renal tubular sodium loss
— overproduction of renin —+ overproduction of aldo-
sterone.
Aldosterone cannot induce potassium loss because
its action on the renal tubule is blocked by progester-
one and 17-hydroxyprogesterone. Its failure to induce
hypertension presumably relates also to the primary
salt loss: hypertension is not characteristic of the
secondary aldosteronism of salt depletion.
The syndrome of juxtaglomerular hyperplasia,
aldosteronism and normal blood pressure as
an error in feedback control
In the syndrome of juxtaglomerular hyperplasia,
hyperaldosteronism, hypokalemic alkalosis and nor-
mal blood pressure [54], the response of blood pressure
to angiotensin II is severely limited, representing from
one-tenth to one one-hundredth of the normal re-
sponse. This limitation is not removed with expansion
of intravascular volume to normal or supernormal
values, nor by restoration of body potassium to
normal. Accordingly, even very large increases in
endogenous renin and angiotensin production fail to
raise blood pressure above normal. Such increases,
which persist even in the face of induced hypervolemia,
can stimulate aldosterone production, which becomes
excessive, and this in turn can induce hypokalemia by
renal loss; the hypokalemia in turn may limit further
aldosterone production. It probably also potentiates
further overproduction of renin.
In some patients with a syndrome similar to this, a
persistent obligatory renal loss of sodium appears to be
present [55]. In this group of patients an error of feed-
back control of renal and adrenal function may occur,
according to the following sequence of events: oblig-
atory renal tubular sodium loss — hypovolemia —-
109
Fig. 5. Effect of high and low sodium intakes on aldosterone secre-
tion rates in normal subjects (0), in patients with adrenogenital
syndrome of the salt-losing type () and of the non-salt-losing
type (A).
overproduction of renin —-overproduction of aldo-
sterone — hypokalemiabecause of aldosterone-stimul-
ated renal loss. According to this sequence, the resis-
tance of blood pressure to exogenous angiotensin is
interpreted as a change secondary to the hypovolemia
[56].
This sequence of events will not explain the syn-
drome in patients [57] who conserve sodium normally.
It will probably not explain the extreme resistance to
angiotensin found in most patients with this syndrome,
which is one or more orders of magnitude greater than
the resistance found with simple sodium deprivation.
In the patients who conserve sodium normally, another
sequence of events must be invoked to explain the
pathophysiology. For this we have suggested the most
satisfactory sequence according to current concepts as
resistance to angiotensin —- tendency to hypotension —-
overproduction of renin —±overproduction of aldo-
sterone —> hypokalemia. The hypokalemia may limit
further production of aldosterone while inducing even
greater production of renin. This may explain the find-
ing in some of these patients of very high plasma renin
values together with only moderate elevation of aldo-
sterone production (F. C. Bartter, unpublished
observations).
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Fig. 6. Averaged figures of urine fiow/glomerular filtration rate(V/GFR) under conditions of maximal free water clearance for
four patients with the syndrome of juxtaglomerular hyperplasia
contrasted with the results in 12 normal young women.
A further defect in renal function is regularly found
in patients with this syndrome. Under conditions of
maximal free water clearance, they manifest 1)excessive
delivery of proximal tubular fluid to distal sites, and
2) a limitation in the percentage of such fluid which is
converted to "free" water by reabsorption of sodium.
This second limitation is especially prominent in view
of the excessive production of aldosterone shown by
most subjects. Fig. 6 shows averaged figures for urine
flow/GFR (V/GFR) under conditions of maximum
free water clearance for four patients with this syn-
drome contrasted to the results in 12 normal young
women. Whereas delivery of proximal fluid to distal
sites may be very high in the subjects, their ability to
convert such fluid to free water is limited.
Rubini found a limitation in maximum urine flow
and in minimal urinary osmolality resulting from ex-
perimental potassium depletion in man [58].
Fig. 7 shows these results plotted as the relationship
between the fraction of fluid delivered distally which is
converted to free water,CH2O/CHZO + CNa, to the frac-
tion so delivered, CH2O + CNa/GFR. Results in normal
subjects show that from 7 to l7% of the filtered fluid is
delivered distally under these conditions of maximal
free water clearance. Of the fluid so delivered, 80% is
converted to free water. In the patients, on the other
hand, some 10 to 35% of the filtrate is delivered
to distal sites, but the percentage converted to free
.80
z
C..) .60
.40
L)
.20
Patient 1 0
Patient 2 A
Patient 3 0
Patient 4 0
Controls u
Patient 1
Patient 2
Patient 3 ®
Patient 4 0
Controls U
4 8 12 16 20 24 28 32 36
CH2O + CN
CIN
Fig. 8. Relationship of free water clearance to fluid delivered
distally.
water varies from l9% in patient ito 70% in patient 3.
Fig. 8 shows these results in another way, representing
the relationship of free water clearance to fluid de-
livered distally. It is again apparent that patients 1 and
2, delivering relatively normal percentages of filtrate
distally, showed severe limitation in free water clear-
ance, whereas patients 3 and 4 could produce normal
amounts of free water (expressed as percentages of
GFR) only by delivery of very large amounts of
filtrate to the distal tubules.
This last figure shows also the results of the three
published papers giving studies of this type in patients
with this syndrome [59—61]. It is apparent that the
patient described by Chaimowitz et a! closely re-
sembled our patient 2, whereas the patient described
by Chan, Malekzadeh and Anand closely resembled
our patient 4 in the indexes here reported.
This abnormality of renal function in this syndrome
suggests that another sequence of events may play a
Q Patient 4
30
Q Patient 1 Patient 3
1.L0
8
Patient 5
Patient 6
20
16
al2
8
4
0
CI
tChe
S
haj
48 121602428 32 36
C020 + C,
C10
Fig. 7. Relationship of the fract ion of fluid delivered distally which
is converted to free water to the fraction so delivered.
0 5 10 15 20 25
• •.% •
.•• •S 1
00
0
Adrenal cortex and the kidney 279
part, to wit, under conditions of maximum free water
clearance: water loading —÷expansion of extracellular
fluid volume — abnormal decrease in proximal tubu-
lar reabsorption —- limitation of sodium reabsorption
— excessive sodium loss. Despite the increased de-
livery of proximal fluid to distal sites, the limitation of
free water production should result in retention of free
water, and further hypotonic expansion of extracel-
lular fluid volume. Such expansion might in turn
augment the defect in proximal tubular reabsorption.
In four patients with this syndrome functional gb-
merulo-distal-tubular shunts have been described [62].
This lesion, which has been interpreted to represent
early glomerulitis, allows the filtrate to escape from the
glomerulus into the interstitial area and occasionally
into the distal tubule. Since the epithelium remains
intact despite destruction of basement membrane,
formed elements are prevented from following this
route. Such a lesion might, by delivery of proximal
fluid into the distal convoluted tubule, stimulate pro-
duction of renin by the action of sodium on the macula
densa [63]. It might also explain the apparent delivery
of excessive amounts of proximal fluid distally, with
limitation in the production of free water from such
fluid, which would never be exposed to the ascending
limb of the loop of Henle.
Whereas the resistance of blood vessels to angio-
tensin appears to be the most "proximal" event in the
sequence manifested by this syndrome, the ultimate
cause of such resistance remains the subject of future
investigation.
Reprint requests to Dr. Frederic C. Bartter, Hypertension-
Endocrine Branch, National Heart and Lung Institute, National
Institutes of Health, Bethesda, Maryland 20014, U.S.A.
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